Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Treasury Shares (2019 - 2025)

Historic Treasury Shares for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • C4 Therapeutics' Treasury Shares rose 4318347.9% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 4318347.9%. This contributed to the annual value of $1.5 million for FY2024, which is 10064.9% up from last year.
  • Per C4 Therapeutics' latest filing, its Treasury Shares stood at $2.9 million for Q3 2025, which was up 4318347.9% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Treasury Shares peaked at $3.0 million during Q2 2025, and registered a low of $6634.0 during Q3 2024.
  • Its 4-year average for Treasury Shares is $1.0 million, with a median of $704330.0 in 2023.
  • Its Treasury Shares has fluctuated over the past 5 years, first plummeted by 9912.24% in 2024, then soared by 4318347.9% in 2025.
  • Quarter analysis of 4 years shows C4 Therapeutics' Treasury Shares stood at $465291.0 in 2022, then soared by 61.23% to $750210.0 in 2023, then surged by 100.65% to $1.5 million in 2024, then soared by 90.76% to $2.9 million in 2025.
  • Its Treasury Shares stands at $2.9 million for Q3 2025, versus $3.0 million for Q2 2025 and $1.5 million for Q4 2024.